article thumbnail

3rd In Vivo Cell Engineering & Gene Editing Summit

pharmaphorum

Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic

In-Vivo 52
article thumbnail

$175M financing will support development of in vivo CAR-T therapies

Drug Discovery World

The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing.

In-Vivo 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug

XTalks

Intellia said NTLA-2001 is the first investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development. As an in vivo therapy, it can edit genes inside the body rather than in cells extracted from patients. ATTR amyloidosis is a rare, progressive and fatal disease.

In-Vivo 52
article thumbnail

Neurons in spinal-cord injuries are reconnected in vivo via carbon nanotube sponges

Scienmag

CIC biomaGUNE researchers have demonstrated the restoring in vivo of the connection between neurons, yielding functional results Credit: Author: Pedro Ramos / CIC biomaGUNE Research conducted by two groups at the Center for Cooperative Research in Biomaterials CIC biomaGUNE and one at SISSA, Scuola Internazionale Superiore di Studi Avanzati (Italy), (..)

In-Vivo 96
article thumbnail

Intellia Establishes Proof-of-Concept for in vivo CRISPR Bone Marrow Editing

BioSpace

Intellia Therapeutics presented preclinical data of its non-viral genome editing platform at the Keystone eSymposium: Precision Engineering of the Genome, Epigenome and Transcriptome.

In-Vivo 98
article thumbnail

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Pharmaceutical Technology

The company can use its mammalian cell engineering expertise and capabilities to screen CAR T-cells, to discover and optimise next-generation therapeutic candidates for its partners. All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models.

In-Vivo 264
article thumbnail

New microrobot with in situ, in vivo bioprinting offers promise for gastric wounds

Scienmag

Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body.

In-Vivo 72